Prognostic factors and outcome in patients with T1 high-grade bladder cancer: Can we identify patients for early cystectomy?

BJU International

Volumn 109, Issue 7, 2012, Pages 1026-1030

  Segal, Robert ^a   Yafi, Faysal A ^a   Brimo, Fadi ^b   Tanguay, Simon ^a   Aprikian, Armen ^a   Kassouf, Wassim ^a  

^a Salvation Army Scarborough Grace H   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

architecture; BCG; cystectomy; prognostic factors; superficial bladder cancer; T1

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORPHOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CYSTECTOMY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; TRANSURETHRAL RESECTION; WORSENING FREE SURVIVAL;

AGED; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84858444672     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10462.x     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300
2. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC,. A study comparing various non-invasive methods of detecting bladder cancer in urine. BJU Int 2002; 89: 369-73 (Pubitemid 34304360)
3. Kassouf W, Kamat AM, Zlotta A, et al,. Canadian guidelines for treatment of no-muscle invasive bladder cancer-a focus on intravesical therapy. Can Urol Assoc J 2010; 4: 168-73
4. Heney NM, Nocks BN, Daly JJ, et al,. Ta and T1 bladder cancer: location, recurrence and progression. BJU Int 1982; 54: 152-7 (Pubitemid 12120209)
5. Schwaibold HE, Sivalingam S, May F, Hartung R,. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006; 97: 1199-201 (Pubitemid 43907321)
6. Herr HW,. Age and outcome of superficial bladder cancer treated with Bacille Calmette-Guerin therapy. Urology 2007; 70: 65-8 (Pubitemid 47081102)
7. Dalbagni G, Vora K, Kaag M, et al,. Clinical outcome in a contemporary series fo restaged patients with clinical T1 bladder cancer. Eur Urol 2009; 56: 903-10
8. Shariat SF, Zippe C, Ludecke G, et al,. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005; 173: 1518-25 (Pubitemid 40524761)
9. Lamm DL, Blumenstein BA, Crissman JD, et al,. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000; 163: 1124-9 (Pubitemid 30169376)
10. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL,. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987; 137: 220-4 (Pubitemid 17016634)
11. Bianco JFJ, Justa D, Grignon DJ,. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004; 22: 290-4 (Pubitemid 38996784)
12. Breau R, Leibovich B, Karnes R, et al,. Early cystectomy prior to muscle invasion improves cancer survival in patients with urothelial carcinoma. Annual Meeting of the Canadian Urological Association, Toronto, Ontario, 30 June 2009
13. Soloway MS, Sofer M, Vaidya A,. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-83 (Pubitemid 34240678)
14. Joudi FN, Smith BJ, O Donnell, National. MA,. BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006; 24: 344-8 (Pubitemid 43963411)
15. Dalbagni G, Russo P, Bochner B, et al,. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24: 2729-34 (Pubitemid 46630569)
16. Dalbagni G, Kaag M, Cronin A, et al,. Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. BJU Int 2010; 106: 1502-7
17. Wedel SA, Jones J, Tsaur I, et al,. Association of intravesical tumor location with metastases to the pelvic lymph nodes in transitional cell cancer of the bladder. Am J Med Sci 2010; 339: 341-4
18. Donat SM, Genega EM, Herr HW, Reuter VE,. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol 2001; 165: 1117-20 (Pubitemid 32210215)
19. Pagano F, Bassi P, Ferrante GL, et al,. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 1996; 155: 244-7 (Pubitemid 126426473)
20. Esrig D, Freeman JA, Elmajian DA, et al,. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996; 156: 1071-6 (Pubitemid 26269831)
21. Alkhateeb SS, Van Rhijn BW, Finelli A, et al,. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 2010; 184: 81-6
22. Fahmy N, Kassouf W, Jeyaganth S, et al,. An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec. Can Urol Assoc J 2008; 2: 102-8
23. Herr HW,. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74-6 (Pubitemid 29420883)
24. Herr HW,. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005; 174: 2134-7 (Pubitemid 41611754)
25. Remzi M, Haitel A, Margulis V, et al,. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2008; 103: 307-11
26. Kim DS, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ,. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology 2010; 75: 328-33